Compugen Second Quarter 2016 Conference Call Scheduled for Tuesday, August 2, 2016 at 10:00 AM ET

HOLON, Israel, July 21, 2016

Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, August 2, 2016 to review the second quarter 2016 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.

To access the conference call, please dial 1-888-407-2553 from the US, or +972-3-918-0685 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. A replay of the conference call will be available beginning approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-326-9310 from the US or +972-3-925-5925 internationally. The replay will be available through August 4, 2016.

About Compugen  

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892

SOURCE Compugen Ltd.